Compare
908 Devices Inc. vs Harvard Bioscience Inc vs Rapid Micro Biosystems, Inc. vs EyePoint, Inc.
| Latest fiscal year | 908 Devices Inc. MASS | Harvard Bioscience Inc HBIO | Rapid Micro Biosystems, Inc. RPID | EyePoint, Inc. EYPT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $56.20M | $86.55M | $33.59M | $31.37M |
| Revenue growth (YoY) | +17.7% | -8.1% | +19.7% | -27.5% |
| Gross margin | 50.6% | 57.7% | n/a | n/a |
| Operating margin | -70.1% | -56.1% | -141.1% | -776.0% |
| Net margin | 34.7% | -65.5% | -140.3% | -739.4% |
| Net income | $19.49M | -$56.70M | -$47.12M | -$231.96M |
| EPS (Diluted) | $0.54 | -$1.28 | -$1.05 | -$3.17 |
| Operating cash flow | -$23.69M | $6.73M | -$31.06M | -$240.11M |
| Free cash flow | -$24.64M | $5.47M | -$31.91M | -$243.39M |
| Cash & equivalents | $70.52M | $8.61M | $20.03M | $101.82M |
| Total assets | $190.07M | $80.07M | $74.85M | $364.00M |
| Total liabilities | $46.37M | $66.34M | $41.65M | $57.88M |
| Shareholders' equity | $143.70M | $13.73M | $33.21M | $306.11M |
| Return on year-end equity | 13.6% | -412.8% | -141.9% | -75.8% |
| Shares outstanding | 36.32M | 44.72M | n/a | 82.83M |
Revenue, most recent five fiscal years
| Fiscal year | 908 Devices Inc. | Harvard Bioscience Inc | Rapid Micro Biosystems, Inc. | EyePoint, Inc. |
|---|---|---|---|---|
| Latest | $56.20M Ended 2025-12-31 | $86.55M Ended 2025-12-31 | $33.59M Ended 2025-12-31 | $31.37M Ended 2025-12-31 |
| 1 year earlier | $47.75M Ended 2024-12-31 | $94.14M Ended 2024-12-31 | $28.05M Ended 2024-12-31 | $43.27M Ended 2024-12-31 |
| 2 years earlier | $50.23M Ended 2023-12-31 | $112.25M Ended 2023-12-31 | $22.52M Ended 2023-12-31 | $46.02M Ended 2023-12-31 |
| 3 years earlier | $46.85M Ended 2022-12-31 | $113.33M Ended 2022-12-31 | $17.13M Ended 2022-12-31 | $41.40M Ended 2022-12-31 |
| 4 years earlier | $42.21M Ended 2021-12-31 | $118.90M Ended 2021-12-31 | $23.23M Ended 2021-12-31 | $36.94M Ended 2021-12-31 |